FDA approves avelumab as frontline maintenance in urothelial carcinoma

The FDA has approved the PD-L1 inhibitor avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.

Advanced PCa: How evolving treatment approaches impact patient care

Experts highlight recent clinical data and its implications for diagnosis and treatment.